JAMA Personal Drug Importation Correction

PSM’s executive director submitted the following correction to the Journal of the American Medical Association (JAMA) in December 2024: International online pharmacies are illegal, and an unacceptable cost-saving strategy  Shabbir Safdar Executive Director, The Partnership for Safe Medicines JAMA’s October 21, 2024 Special Communication, “Strategies to Help Patients Navigate High Prescription Drug Costs,” by Hussain…

[...]

Prescription Drug Affordability Board Activity through November 15, 2024

Colorado’s board reviewed proposed changes to PDAB legislation based on stakeholder testimony and board review and learned about Medicare’s Maximum Fair Price (MFP) determination. Over two meetings, Oregon’s board reviewed a draft constituent group engagement report and a UPL model that analyzed potential 2023 savings based upon MFP provided by their consultants and aggregate data collected from PBMs. The board also discussed ; policy recommendations from staff and a UPL draft report required by Senate Bill 192.

[...]

FDA Alert: Dietary Supplement Recalled Due to Presence of Sildenafil and Diclofenac

Consumption of products with undeclared sildenafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may cause a significant drop in blood pressure that may be life threatening. People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Among the adult male population, who are most likely to use this product, adult males who use nitrates for cardiac conditions are most at risk.

[...]

FDA Alert: Dietary Supplement Contains Drug That Can Cause Heart Attack, Stroke and Internal Bleeding

Use of products with undeclared diclofenac may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.

[...]

FDA Alert: Compounding Pharmacy in California Warned After Particulates Found in Injections

On August 14, 2024, FDA received a complaint from a patient who noticed a black particulate in a vial of semaglutide distributed by Fullerton Wellness. On September 23, 2024, FDA received information from California regulatory authorities as part of ongoing collaboration between FDA and the state noting deficiencies found at Fullerton Wellness during a state inspection. After the state inspection, Fullerton Wellness voluntarily ceased operations.

[...]